This reflects the state of play as of early 2026: States that cover GLP-1s for obesity treatment (fee-for-service): Arkansas, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Mexico, New York, Oregon, Virginia, Washington approximately 13 states total as of January 2026
Pharmacists and the prescribing health care provider should help with any questions about dosing
But we have to be careful not to forget the men
This study was prior to the use of GLP-1 drugs for obesity, so these findings are applicable to people with diabetes
Patients researching tirzepatide dosing for weight loss found that cost, not dosing, had become their primary concern